As of May 2025, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising for a fourth consecutive week amid optimism over easing trade tensions between China and the U.S. This positive sentiment is further buoyed by Germany's robust industrial output and recent monetary policy adjustments across several European countries. In such an environment, growth companies with high insider ownership can be particularly appealing to investors seeking alignment between management interests and shareholder value, as these traits may indicate confidence in the company's future prospects amidst evolving market dynamics.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 11.8% | 43.1% |
| KebNi (OM:KEBNI B) | 38.3% | 66.1% |
| Yubico (OM:YUBICO) | 36.5% | 30.4% |
| Bergen Carbon Solutions (OB:BCS) | 12% | 63.2% |
| Vow (OB:VOW) | 13.1% | 81% |
| Elicera Therapeutics (OM:ELIC) | 23.8% | 97.2% |
| CD Projekt (WSE:CDR) | 29.7% | 37.4% |
| Elliptic Laboratories (OB:ELABS) | 22.6% | 51.9% |
| Norbit (OB:NORBT) | 13.2% | 26.6% |
| Nordic Halibut (OB:NOHAL) | 29.7% | 60.7% |
We'll examine a selection from our screener results.
Ambu (CPSE:AMBU B)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Ambu A/S is a medical technology company that develops, produces, and sells medical devices to hospitals, clinics, and rescue services globally, with a market cap of DKK27.81 billion.
Operations: The company's revenue is derived from Disposable Medical Products, amounting to DKK5.83 billion.
Insider Ownership: 24.9%
Earnings Growth Forecast: 24.8% p.a.
Ambu A/S demonstrates strong growth prospects with earnings forecasted to increase by 24.8% annually, outpacing the Danish market's 7.7%. Recent financial results show robust performance, with second-quarter sales rising to DKK 1.55 billion and net income reaching DKK 188 million. Despite trading at a discount of 17.6% below its estimated fair value, Ambu's revenue is expected to grow at a rate of 10.2%, surpassing the broader market's pace of 8.2%.
- Click here and access our complete growth analysis report to understand the dynamics of Ambu.
- Insights from our recent valuation report point to the potential overvaluation of Ambu shares in the market.
Surgical Science Sweden (OM:SUS)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Surgical Science Sweden AB (publ) specializes in developing and marketing virtual reality simulators for evidence-based medical training globally, with a market cap of SEK7.69 billion.
Operations: The company's revenue is derived from two main segments: Industry/OEM, contributing SEK441.59 million, and Educational Products, accounting for SEK442.50 million.
Insider Ownership: 14.8%
Earnings Growth Forecast: 34.4% p.a.
Surgical Science Sweden shows promising growth potential, with earnings forecasted to grow 34.4% annually, significantly outpacing the Swedish market's 16.4%. The company reported strong Q1 results with sales of SEK 250.69 million and net income of SEK 33.24 million, despite a decline in profit margins from last year. Trading at a substantial discount to its estimated fair value, it presents an attractive opportunity for investors focused on growth companies with high insider ownership levels in Europe.
- Unlock comprehensive insights into our analysis of Surgical Science Sweden stock in this growth report.
- Our expertly prepared valuation report Surgical Science Sweden implies its share price may be lower than expected.
Straumann Holding (SWX:STMN)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Straumann Holding AG is a global provider of tooth replacement and orthodontic solutions, with a market capitalization of CHF17.99 billion.
Operations: Straumann Holding AG generates revenue through its operations in various regions, including CHF1.32 billion from Operations, CHF0.59 billion from Sales in Asia Pacific (APAC), CHF0.79 billion from Sales in North America (NAM), CHF0.29 billion from Sales in Latin America (LATAM), and CHF1.11 billion from Sales in Europe, Middle East and Africa (EMEA).
Insider Ownership: 32.3%
Earnings Growth Forecast: 13.4% p.a.
Straumann Holding demonstrates robust growth potential, with revenue forecasted to grow at 9.6% annually, surpassing the Swiss market's 4.2%. Recent innovations like the Straumann AXS platform enhance its digital workflow capabilities in dentistry. The appointment of Isabelle Adelt as CFO may strengthen financial strategy. Despite a high P/E ratio of 39.3x, slightly below industry average, insider ownership remains significant without recent substantial insider trading activity, supporting its position among European growth stocks with high insider involvement.
- Click here to discover the nuances of Straumann Holding with our detailed analytical future growth report.
- Our expertly prepared valuation report Straumann Holding implies its share price may be too high.
Seize The Opportunity
- Click this link to deep-dive into the 209 companies within our Fast Growing European Companies With High Insider Ownership screener.
- Contemplating Other Strategies? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Surgical Science Sweden might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com